1 of study treatment, and therefore was not a
treatment-emergent adverse event).
2 in the ixekizumab Q2W group had at least one
treatment-emergent adverse event.
3 n the placebo group had at least one serious
treatment-emergent adverse event.
4 each in the 6- and 20-mg cohorts) died of a
treatment-emergent adverse event.
5 All patients had at least one
treatment-emergent adverse event.
6 tients in the control group had at least one
treatment-emergent adverse event.
7 501 (98.0%) of 511 patients had at least one
treatment-emergent adverse event.
8 All 11 patients had at least one
treatment-emergent adverse event.
9 l or allergic reactions and no difference in
treatment emergent adverse events.
10 at least one dose of study drug in terms of
treatment-emergent adverse events.
11 avenously evinacumab versus placebo reported
treatment-emergent adverse events.
12 37%; no grade 3 or 4) being the most common
treatment-emergent adverse events.
13 ent-emergent serious adverse events, and all
treatment-emergent adverse events.
14 lerated, with few significant differences in
treatment-emergent adverse events.
15 ceived adalimumab plus methotrexate reported
treatment-emergent adverse events.
16 and dizziness were the most common (>/=20%)
treatment-emergent adverse events.
17 (69%) and nausea (49%) were the most common
treatment-emergent adverse events.
18 al sign changes, soft-tissue anesthesia, and
treatment-emergent adverse events.
19 oints included the frequency and severity of
treatment-emergent adverse events.
20 as no apparent dose-response relationship in
treatment-emergent adverse events.
21 patients in the bimekizumab groups reported
treatment-emergent adverse events.
22 Safety assessments included
treatment-emergent adverse events.
23 ety end point was the number and severity of
treatment-emergent adverse events.
24 90 patients in the placebo group had serious
treatment-emergent adverse events.
25 bjects on evinacumab versus placebo reported
treatment-emergent adverse events.
26 mary outcomes were incidence and severity of
treatment-emergent adverse events.
27 There were no drug-related deaths due to
treatment-emergent adverse events.
28 patients in the placebo group) or a serious
treatment-emergent adverse event (
101 [29%] patients vs
29 f patients in the two treatment groups had a
treatment-emergent adverse event (
295 [84%] of 353 patie
30 147 (67%) patients experienced at least one
treatment-emergent adverse event (
36 [64%] in the CT-P13
31 , the proportion of patients who experienced
treatment-emergent adverse events (
79% [1125 of 1432 pat
32 Most patients experienced at least one
treatment-emergent adverse event (
87.8% in AZD9773-treat
33 The most common grade 3-4
treatment-emergent adverse events across all doses were
34 We analyzed
treatment-emergent adverse events (
AEs) and laboratory a
35 Safety assessment included recording of
treatment-emergent adverse events (
AEs) and serious AEs.
36 The most common
treatment-emergent adverse events (
AEs) in patients acro
37 The proportion of patients with >/= 1
treatment-emergent adverse events (
AEs) was similar acro
38 Overall incidence of
treatment-emergent adverse events (
AEs) was similar betw
39 Treatment-emergent adverse events (
AEs) were mostly grad
40 All
treatment-emergent adverse events (
AEs) were recorded an
41 two patients (85%) experienced >=1 grade 3/4
treatment-emergent adverse events (
AEs), most commonly n
42 Treatment-emergent adverse events (
AEs), muscle-related
43 Treatment-emergent adverse events and laboratory abnorma
44 43 (10%) taking carbamazepine-CR had serious
treatment-emergent adverse events,
and 47 (11%) and 69 (
45 Main outcome measures were safety, including
treatment-emergent adverse events,
and efficacy, includi
46 For our analysis, rates of SVR12,
treatment-emergent adverse events,
and graded laboratory
47 seven patients (42%) experienced grade >/= 3
treatment-emergent adverse events,
and one dose-limiting
48 lation time (RCT), retinal blood flow (RBF),
treatment-emergent adverse events,
and other safety para
49 d as the number of patients with one or more
treatment-emergent adverse events,
and skeletal manifest
50 ents treated with pravastatin (70%) reported
treatment-emergent adverse events,
and these caused stud
51 The most frequent
treatment-emergent adverse events (
any grade; isatuximab
52 ho received Nexvax2 150 mug had at least one
treatment-emergent adverse event,
as did all three (100%
53 ho received Nexvax2 300 mug had at least one
treatment-emergent adverse event,
as did six (86%) of se
54 of 106 patients in the eliglustat group had
treatment-emergent adverse events,
as did 42 (79%) of 53
55 e most frequently reported treatment-related
treatment-emergent adverse events being fatigue, constip
56 l or allergic reactions and no difference in
treatment-emergent adverse events between the groups (64
57 The frequencies of
treatment-emergent adverse events between the groups wer
58 Proportions of patients with
treatment-emergent adverse events by system organ class
59 mg groups, respectively) withdrew because of
treatment-emergent adverse events compared with nine (15
60 Treatment-emergent adverse events considered possibly, p
61 uded in the safety analysis had at least one
treatment-emergent adverse event deemed to be related to
62 rred in 523 (75%) of 696 patients; any-grade
treatment-emergent adverse events deemed to be related t
63 Incidence of
treatment-emergent adverse events did not differ between
64 Treatment-emergent adverse events did not differ between
65 e), but the proportion of patients reporting
treatment-emergent adverse events did not differ from pl
66 Myalgia was the most common
treatment-emergent adverse event during the study, occur
67 The most common grade >=3
treatment-emergent adverse events during induction were
68 Treatment-related
treatment-emergent adverse events during the 12-month st
69 Treatment-emergent adverse events (
eg, insomnia, akathis
70 Serious
treatment-emergent adverse events (
excluding neoplasm pr
71 One patient (<1%) had a grade 3
treatment-emergent adverse event (
fatigue); no patients
72 The most common
treatment-emergent adverse event for brexpiprazole was a
73 The most common grade 3 or 4
treatment-emergent adverse event in each treatment group
74 The most common grade 3-4
treatment-emergent adverse event in groups A, B, and C w
75 The most common grade 3 or 4
treatment-emergent adverse event in patients allocated l
76 Grade 3 or worse treatment-related
treatment-emergent adverse events in 5% or more of patie
77 We noted
treatment-emergent adverse events in 613 (98%) of 627 pa
78 The most common
treatment-emergent adverse events in all 32 patients wer
79 Serious
treatment-emergent adverse events in more than one patie
80 e nausea and vomiting were the most frequent
treatment-emergent adverse events in omadacycline (111 [
81 The most frequent (> 30%)
treatment-emergent adverse events in patients with GIST
82 ver aminotransferases were the most frequent
treatment-emergent adverse events in phase III studies b
83 Grade >/= 3
treatment-emergent adverse events in the amrubicin and t
84 Overall, 32 patients reported 56
treatment-emergent adverse events in the EMA401 group co
85 The most common
treatment-emergent adverse events in the ixekizumab grou
86 The most common grade 3-4
treatment-emergent adverse events in the ramucirumab plu
87 common (>2%) grade 3 or 4 treatment-related
treatment-emergent adverse events in the ripretinib grou
88 The most commonly reported treatment-related
treatment-emergent adverse events in the rolapitant vers
89 The incidence of
treatment-emergent adverse events in the safety populati
90 43 (10%) of 155
treatment-emergent adverse events in the solithromycin g
91 The most frequent
treatment-emergent adverse events in the sorafenib group
92 Common
treatment-emergent adverse events (
in at least 5% of par
93 The most frequent grade 3 or worse
treatment-emergent adverse events included anaemia (13 [
94 Frequent grade 3 or worse
treatment-emergent adverse events included anaemia (19 [
95 The most common
treatment-emergent adverse events included hyperphosphat
96 The most common
treatment-emergent adverse events included infections wi
97 Treatment-emergent adverse events included sedation, cha
98 to-moderate XR-NTX injection site reactions,
treatment-emergent adverse events including overdose did
99 Most
treatment-emergent adverse events,
including hypokalemia
100 The incidence of
treatment-emergent adverse events,
including infections
101 group and 17 (89%) in the AMG 714 group had
treatment-emergent adverse events,
including one (11%) p
102 Overall, 136 patients experienced
treatment-emergent adverse events,
including six serious
103 ne patient in the placebo group had a severe
treatment-emergent adverse event (
insomnia).
104 One
treatment-emergent adverse event leading to withdrawal f
105 Treatment-emergent adverse events leading to death occur
106 Treatment-emergent adverse events leading to discontinua
107 No serious adverse events or
treatment-emergent adverse events leading to discontinua
108 icipants in the interferon beta-1a group had
treatment-emergent adverse events leading to treatment d
109 Treatment-emergent adverse events led to discontinuation
110 en (59 [98%] of 60 children) had one or more
treatment-emergent adverse events;
most events were mild
111 Treatment-emergent adverse events,
mostly described as m
112 (80%) of 61 patients given placebo reported
treatment-emergent adverse events;
nasopharyngitis was t
113 ts in the clinical management group reported
treatment-emergent adverse events;
no treatment-related
114 The
treatment-emergent adverse events observed were generall
115 At least one serious
treatment-emergent adverse event occurred for 22 (19%) p
116 At least 1
treatment-emergent adverse event occurred in 86%, 92%, a
117 Serious
treatment-emergent adverse events occurred in 11 (25%) p
118 Treatment-emergent adverse events occurred in 136 (50%)
119 Serious
treatment-emergent adverse events occurred in 160 (41%)
120 Treatment-emergent adverse events occurred in 20.1% of t
121 Treatment-emergent adverse events occurred in 21 (95%) p
122 Treatment-emergent adverse events occurred in 224 (99%)
123 Serious
treatment-emergent adverse events occurred in 23 (29%) o
124 71 severe
treatment-emergent adverse events occurred in 25 (27%) p
125 Treatment-emergent adverse events occurred in 277 (72%)
126 Treatment-emergent adverse events occurred in 277 (84%)
127 Grade 3-4
treatment-emergent adverse events occurred in 34 (44%) o
128 Any-grade
treatment-emergent adverse events occurred in 523 (75%)
129 Treatment-emergent adverse events occurred in 62.3% of p
130 Local
treatment-emergent adverse events occurred in 7 patients
131 Treatment-emergent adverse events occurred in 76 (70%) o
132 Serious
treatment-emergent adverse events occurred in 93 (48%) p
133 Grade >= 3
treatment-emergent adverse events occurred in 96% of pat
134 ipants given the MTD, eight gastrointestinal
treatment-emergent adverse events occurred in four (50%)
135 Serious
treatment-emergent adverse events occurred in nine patie
136 Treatment-emergent adverse events occurred in ten (63%)
137 No drug-related serious
treatment-emergent adverse events occurred.
138 No grade 5
treatment-emergent adverse events occurred; 5 patients d
139 The most common
treatment-emergent adverse events occurring in >10% of p
140 Treatment-emergent adverse events occurring significantl
141 The most frequent
treatment-emergent adverse event of grade 3 or higher wa
142 Nine patients had a
treatment-emergent adverse event of grade 3 or higher, m
143 The most common
treatment-emergent adverse events of any grade were diar
144 The most common (in >=20% of patients)
treatment-emergent adverse events of any grade were epis
145 Treatment-emergent adverse events of grade 3 or higher i
146 Treatment-emergent adverse events of grade 3 or worse oc
147 The most common
treatment-emergent adverse events of grade 3 or worse we
148 Of the
treatment-emergent adverse events of special interest, t
149 36 in the placebo group had grade 3 or worse
treatment-emergent adverse events;
of which the most com
150 Four patients had serious
treatment-emergent adverse events (
one patient in the 1.
151 No serious
treatment-emergent adverse events or events leading to d
152 nd 21 (15%) in the placebo group had serious
treatment emergent adverse events (
p=0.63).
153 le and 255 [98%] receiving voriconazole) had
treatment-emergent adverse events (
p=0.122); the most co
154 Evolocumab was well tolerated, and
treatment-emergent adverse events patient incidence was
155 96/121 (79.3%) patients on lacosamide had
treatment-emergent adverse events (
placebo 79/121 (65.3%
156 e not associated with an increase in overall
treatment-emergent adverse event rates or neurocognitive
157 The most frequently reported
treatment-emergent adverse events,
regardless of causali
158 ratory tract infection was the most frequent
treatment-emergent adverse event reported as related to
159 ed than temsirolimus, with grade 3 or higher
treatment-emergent adverse events reported for 94 (68%)
160 The most common grade 3 or worse
treatment-emergent adverse events,
reported in patients
161 treatment-related, and no treatment-related
treatment-emergent adverse event resulted in death.
162 treatment related, and no treatment-related
treatment-emergent adverse events resulted in death.
163 n antidepressant reported significantly more
treatment-emergent adverse events (
RR, 1.07; 95% CI, 1.0
164 The primary endpoint was the incidence of
treatment-emergent adverse events;
secondary endpoints w
165 The primary outcome of the TAUSSIG study was
treatment-emergent adverse events;
secondary outcomes we
166 The most common
treatment-emergent adverse events (
TEAEs) across all gro
167 Patients in the ASP4345 group experienced 73
treatment-emergent adverse events (
TEAEs) and 34 TEAEs w
168 Primary end points included
treatment-emergent adverse events (
TEAEs) and changes fr
169 Safety measures included
treatment-emergent adverse events (
TEAEs) and corneal en
170 Treatment-emergent adverse events (
TEAEs) in each cohort
171 on in which a patient experienced grade >= 3
treatment-emergent adverse events (
TEAEs) or the mean du
172 In both studies,
treatment-emergent adverse events (
TEAEs) reported by 10
173 The most common grade 3-4
treatment-emergent adverse events (
TEAEs) were anaemia (
174 The most frequent any-grade
treatment-emergent adverse events (
TEAEs) were diarrhea
175 Most common nonhematologic
treatment-emergent adverse events (
TEAEs) were diarrhea/
176 Treatment-emergent adverse events (
TEAEs) were recorded.
177 Ocular and treatment-related
treatment-emergent adverse events (
TEAEs) were reported
178 Only a minority of patients (6.1%) reported
treatment-emergent adverse events (
TEAEs), all of which
179 Overall, 53.6% of patients reported
treatment-emergent adverse events (
TEAEs), of whom 26.8%
180 erse event evaluation included collection of
treatment-emergent adverse events (
TEAEs).
181 lyses included the frequency and severity of
treatment-emergent adverse events (
TEAEs).
182 Safety assessments included
treatment-emergent adverse events (
TEAEs).
183 d percentage of responders by age strata and
treatment-emergent adverse events (
TEAEs).
184 ded the BRIEF-A Informant Report, MADRS, and
treatment-emergent adverse events (
TEAEs).
185 adverse event end point was the incidence of
treatment-emergent adverse events (
TEAEs).
186 The distribution of
treatment-emergent adverse events that led to study disc
187 and 47 (11%) and 69 (16%), respectively, had
treatment-emergent adverse events that led to withdrawal
188 Vomiting, nausea, and headache were the only
treatment-emergent adverse events that occurred in at le
189 Grade 3 or worse
treatment-emergent adverse events that occurred in at le
190 The most frequent
treatment-emergent adverse events that occurred more wit
191 patients in the ramucirumab group died from
treatment-emergent adverse events that were judged to be
192 6%) of 511 patients had at least one serious
treatment-emergent adverse event;
the incidence was simi
193 The most commonly reported
treatment-emergent adverse events up to week 25 were gyn
194 patients in the CT-P6 group reported serious
treatment-emergent adverse events versus 22 (8%) of 278
195 Safety assessments included
treatment-emergent adverse events,
vital signs, and chan
196 The most frequent grade >= 3
treatment-emergent adverse event was anemia (25.2%; 29 o
197 The most frequently reported
treatment-emergent adverse event was arthralgia (placebo
198 At least one
treatment-emergent adverse event was experienced by 30-3
199 n acceptable safety profile; the most common
treatment-emergent adverse event was mild/moderate, typi
200 The most common grade >=3
treatment-emergent adverse event was pneumonia, which oc
201 treatment groups, the most common grade 3-4
treatment-emergent adverse event was postoperative wound
202 No serious
treatment-emergent adverse event was reported for more t
203 The incidence of
treatment-emergent adverse events was 35%, 38%, 38%, and
204 The incidence of any
treatment-emergent adverse events was 58.7% for the plac
205 The incidence of
treatment-emergent adverse events was higher in the inte
206 No pattern of
treatment-emergent adverse events was observed at ABI-H0
207 Incidence of
treatment-emergent adverse events was similar across gro
208 The incidence of
treatment-emergent adverse events was similar between th
209 Incidence of
treatment-emergent adverse events was similar between th
210 The incidence of
treatment-emergent adverse events was similar between tr
211 The incidence of
treatment-emergent adverse events was similar in the pru
212 Incidence of
treatment-emergent adverse events was similar in the TAK
213 The proportion of participants with
treatment-emergent adverse events was similar with fidax
214 Treatment emergent adverse events were balanced across t
215 Treatment emergent adverse events were comparable during
216 The most frequently reported
treatment-emergent adverse event were nasopharyngitis, i
217 Discontinuations due to
treatment-emergent adverse events were 10.3% and 27.8% o
218 Rates of study drug discontinuation due to
treatment-emergent adverse events were 2.9% for lefamuli
219 Rates of grade 3 or 4
treatment-emergent adverse events were 41.2%, 60.1%, and
220 Treatment-emergent adverse events were also examined.
221 he most common drug-related grade 3 or worse
treatment-emergent adverse events were anaemia (113 [24%
222 The most common
treatment-emergent adverse events were anaemia (22 [73%]
223 common (>2%) grade 3 or 4 treatment-related
treatment-emergent adverse events were anaemia (three [7
224 st common grade 3 or worse treatment-related
treatment-emergent adverse events were anaemia in 32 (5%
225 The most common grade 3 or worse
treatment-emergent adverse events were anaemia or decrea
226 The most common
treatment-emergent adverse events were anemia (64.8%), t
227 Only two (mild/moderate)
treatment-emergent adverse events were considered relate
228 Treatment-emergent adverse events were consistent with D
229 The most common
treatment-emergent adverse events were diarrhoea (19 [33
230 The most common
treatment-emergent adverse events were diarrhoea and nau
231 The most common
treatment-emergent adverse events were diarrhoea in the
232 Treatment-emergent adverse events were dose dependent.
233 The most commonly reported
treatment-emergent adverse events were dyspnea, cough, a
234 out rates did not differ between groups, and
treatment-emergent adverse events were evenly distribute
235 The most common
treatment-emergent adverse events were fatigue (48%), in
236 The most common
treatment-emergent adverse events were fatigue (62.0%) a
237 For these patients, the most common
treatment-emergent adverse events were fatigue or asthen
238 No severe
treatment-emergent adverse events were found.
239 The most common treatment-related
treatment-emergent adverse events were gastrointestinal
240 The most common
treatment-emergent adverse events were gastrointestinal
241 The most frequently reported
treatment-emergent adverse events were gastrointestinal
242 Treatment-emergent adverse events were generally mild.
243 (66 [64%] of 103 patients); the most common
treatment-emergent adverse events were headache (ten [10
244 The most common
treatment-emergent adverse events were headache, nausea,
245 Most frequent grade 3/4
treatment-emergent adverse events were hematologic (neut
246 The most common grade 3-4
treatment-emergent adverse events were hypertension (43
247 In cohort III,
treatment-emergent adverse events were identical between
248 Most common grade 3-4
treatment-emergent adverse events were indirect hyperbil
249 CYT003 was well tolerated; the most common
treatment-emergent adverse events were injection site re
250 Most
treatment-emergent adverse events were mild to moderate
251 aluren was generally well tolerated and most
treatment-emergent adverse events were mild to moderate
252 All
treatment-emergent adverse events were mild to moderate.
253 Treatment-emergent adverse events were most frequent in
254 The most frequent
treatment-emergent adverse events were nausea (31.0%), c
255 The most common
treatment-emergent adverse events were nausea (in 31 [63
256 The most common
treatment-emergent adverse events were nausea, myelosupp
257 The most common grade 3 or 4
treatment-emergent adverse events were neutropenia (116
258 The most common drug-related grade 3 or 4
treatment-emergent adverse events were neutropenia (25 [
259 The most common grade 3 or worse
treatment-emergent adverse events were neutropenia (35 [
260 The most common related grade 3 or 4
treatment-emergent adverse events were neutropenia, leuk
261 In the highest dose group, more
treatment-emergent adverse events were observed compared
262 Seventy-five
treatment-emergent adverse events were observed in 27 pa
263 Bosutinib had an acceptable safety profile;
treatment-emergent adverse events were primarily managea
264 Grade 3-4
treatment-emergent adverse events were recorded in 21 (3
265 A higher incidence of serious
treatment-emergent adverse events were recorded in patie
266 Treatment-emergent adverse events were reported at simil
267 Treatment-emergent adverse events were reported by 55 (8
268 Treatment-emergent adverse events were reported for 58 (
269 Treatment-emergent adverse events were reported in 103 p
270 Treatment-emergent adverse events were reported in 120 (
271 Treatment-emergent adverse events were reported in 122 (
272 Grade 3-4
treatment-emergent adverse events were reported in 159 (
273 Serious
treatment-emergent adverse events were reported in 18 (1
274 Treatment-emergent adverse events were reported in 253 o
275 Treatment-emergent adverse events were reported in 328 (
276 Treatment-emergent adverse events were reported in 60 (5
277 Serious
treatment-emergent adverse events were reported in 7% of
278 One or more
treatment-emergent adverse events were reported in 78% o
279 Serious
treatment-emergent adverse events were reported in 83 (2
280 Serious
treatment-emergent adverse events were reported in ten (
281 Moderate
treatment-emergent adverse events were reported in two p
282 Incidences of infections and serious
treatment-emergent adverse events were similar across tr
283 Treatment-emergent adverse events were similar between g
284 Rates of
treatment-emergent adverse events were similar between g
285 Types and number of
treatment-emergent adverse events were similar between g
286 Deaths related to
treatment-emergent adverse events were similar between g
287 The proportions of patients affected by
treatment-emergent adverse events were similar in the AL
288 The most common
treatment-emergent adverse events were somnolence (10.0%
289 The most common grade 3/4
treatment-emergent adverse events were thrombocytopenia
290 Other
treatment-emergent adverse events were transient nausea
291 No serious
treatment-emergent adverse events were treatment related
292 rted chemotherapy had acute grade 3 or worse
treatment-emergent adverse events,
which accorded with f
293 s well tolerated; 82 (77%) patients reported
treatment-emergent adverse events,
which were mostly min
294 Ocular
treatment-emergent adverse events,
while uncommon, appea
295 The only
treatment-emergent adverse event with a statistically si
296 disorders were the most frequently reported
treatment-emergent adverse events with both ceftazidime-
297 The most common
treatment-emergent adverse events with DARA-MD 1200 mg w
298 d diarrhea (26.7% each) were the most common
treatment-emergent adverse events with DARA-MD 1800 mg.
299 The primary end point was incidence of
treatment-emergent adverse events within 6 months.
300 The most common non-haematological grade 3-5
treatment-emergent adverse events (
within <=30 days of l